Please ensure Javascript is enabled for purposes of website accessibility

FDA Says, "Call Me Maybe"

By Brian Orelli, PhD - Apr 18, 2013 at 3:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sarepta still doesn't know if it should file for accelerated approval with the FDA.

A lot has been written this week -- at The Fool and elsewhere -- about Sarepta Therapeutics' (SRPT -0.42%) update on its meeting with the Food and Drug Administration. The company is hoping to get an accelerated approval for its Duchenne muscular dystrophy drug, eteplirsen.

Here's my view: It doesn't change a thing.

The biotech has limited phase 2 data, clearly not enough for full approval. The only hope for getting the drug on the market in short order is an accelerated approval. I've pointed out that's both a historical long shot and potentially possible given the FDA's new laxer stance.

Which one will win this battle? We still don't know. Welcome to the ever-changing world of biotech investing.

Under the normal course of events, a company would meet with the FDA after its phase 2 program was complete to decide if the data was worthy of an accelerated approval. If it was an obvious no, the FDA would tell the company to run a phase 3 trial or two. If it was a maybe, the agency would suggest the company submit the full data package so the FDA reviewers could have a closer look.

Occasionally, companies and the FDA seem to have a failure to communicate, such as when Roche (RHHBY -0.38%) received a refuse to file letter after seeking accelerated approval for its breast cancer drug Kadcyla. The agency didn't even want to review the data because it believed that the patients tested in the phase 2 trial didn't have an unmet need, one of the requirements for accelerated approval. Roche and partner ImmunoGen (IMGN -2.54%) recently got the drug approved with more data.

For the most part, though, "no" means "no" and "go ahead and file" means "maybe." There's a certain amount of weeding out those that obviously don't have enough data, but applying is by no means a lock on an approval. Pfizer (PFE 0.65%) asked for accelerated approval for tafamidis meglumine that treats a rare genetic disease, but the FDA rejected the drug, asking for a second clinical trial. Ditto for Cell Therapeutics' (CTIC 3.19%) pixantrone. The biotech appealed the decision, but still hasn't been able to gain approval. Both drugs are approved in Europe, which shows how the FDA has historically not made accelerated approval an easy route.

Sarepta seems like a special case, though. Or perhaps it's the new normal; we'll have to wait and see. Instead of saying "you don't have enough data to file," the agency asked the company for more data to figure out whether it does. That's unusual but not surprising given the new regulatory environment.

And we're essentially back where we started before Sarepta started talking to the agency. Whether eteplirsen is given an approval based on the limited phase 2 data will be determined by how far the FDA wants to relax its regulations.

Without any precedence, it's hard to handicap the decision; invest accordingly.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
SRPT
$68.55 (-0.42%) $0.29
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.76 (0.65%) $0.34
ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
IMGN
$3.45 (-2.54%) $0.09
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$43.06 (-0.38%) $0.17
CTI BioPharma Corp. Stock Quote
CTI BioPharma Corp.
CTIC
$5.33 (3.19%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.